Terms: = Colorectal cancer AND XPA, XPAC, 7507, ENSG00000136936, XP1, P23025 AND Clinical Outcome
4 results:
1. Nucleotide excision repair pathway gene polymorphisms are associated with risk and prognosis of colorectal cancer.
Li YK; Xu Q; Sun LP; Gong YH; Jing JJ; Xing CZ; Yuan Y
World J Gastroenterol; 2020 Jan; 26(3):307-323. PubMed ID: 31988591
[TBL] [Abstract] [Full Text] [Related]
2. Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial.
Boige V; Mollevi C; Gourgou S; Azria D; Seitz JF; Vincent M; Bigot L; Juzyna B; Miran I; Gerard JP; Laurent-Puig P
Int J Cancer; 2019 Dec; 145(11):3163-3172. PubMed ID: 31107542
[TBL] [Abstract] [Full Text] [Related]
3. Single nucleotide polymorphisms in nucleotide excision repair genes xpa, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
[TBL] [Abstract] [Full Text] [Related]
4. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
[TBL] [Abstract] [Full Text] [Related]
